Previous studies identified Axl as a potential therapeutic target in NSCLC, particularly in adenocarcinoma, where Axl expression correlated with tumor progression, malignant behavior of tumor cells, and tumor resistance to chemo- and targeted therapies [9–13]. The gene discussed is AXL; the disease is neoplasm.